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Abstract
Background: Two-thirds of U.S. adult women are overweight or obese. High body mass index (BMI) and adult
weight gain are risk factors for a number of chronic diseases, including postmenopausal breast cancer. The higher
postmenopausal breast cancer risk in women with elevated BMI is likely to be attributable to related metabolic
disturbances including altered circulating sex steroid hormones and adipokines, elevated pro-inflammatory
cytokines, and insulin resistance. Metformin is a widely used antidiabetic drug that has demonstrated favorable
effects on metabolic disturbances and as such may lead to lower breast cancer risk in obese women. Further,
the anti-proliferative effects of metformin suggest it may decrease breast density, an accepted biomarker of
breast cancer risk.
Methods/design: This is a Phase II randomized, double-blind, placebo-controlled trial of metformin in
overweight/obese premenopausal women who have elements of metabolic syndrome. Eligible participants
will be randomized to receive metformin 850 mg BID (n = 75) or placebo (n = 75) for 12 months. The primary
endpoint is change in breast density, based on magnetic resonance imaging (MRI) acquired fat-water features.
Secondary outcomes include changes in serum insulin levels, serum insulin-like growth factor (IGF)-1 to insulin-like
growth factor binding protein (IGFBP)-3 ratio, serum IGF-2 levels, serum testosterone levels, serum leptin to
adiponectin ratio, body weight, and waist circumference. Exploratory outcomes include changes in metabolomic
profiles in plasma and nipple aspirate fluid. Changes in tissue architecture as well as cellular and molecular targets
in breast tissue collected in a subgroup of participants will also be explored.
Discussion: The study will evaluate whether metformin can result in favorable changes in breast density, select
proteins and hormones, products of body metabolism, and body weight and composition. The study should help
determine the potential breast cancer preventive activity of metformin in a growing population at risk for multiple
diseases.
Trial registration: ClinicalTrials.gov Identifier: NCT02028221. Registered on January 2, 2014. Grant #: 1R01CA172444-01A1
awarded on Sept 11, 2013.
Keywords: Metformin, Breast cancer prevention, Breast density, Biomarkers, Metabolic syndrome, Metabolomics
* Correspondence: jam1@email.arizona.edu
1The University of Arizona Cancer Center, 1515 N Campbell Ave; Rm 2964B,
Tucson, AZ 85724, USA
2Department of Nutritional Sciences, The University of Arizona, Tucson, AZ,
USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Martinez et al. BMC Cancer  (2016) 16:500 
DOI 10.1186/s12885-016-2551-3
Background
Obesity and breast cancer
It is predicted that by 2030 there will be 65 million more
obese adults in the USA which will contribute to
492,000–669,000 additional cases of cancer [1]. In
addition to cancer, high body mass index (BMI) is a major
risk factor for a number of chronic diseases, including
type 2 diabetes and cardiovascular diseases [2–5]. For
postmenopausal breast cancer, a high BMI has been
reported to increase risk by 30–50 % [6]. The increased
risk for postmenopausal breast cancer in women with
high adiposity is likely attributed to multiple metabolic
disturbances that occur with overweight and obesity
including, but not limited to, altered circulating sex
steroid hormones, hyperinsulinemic insulin resistance,
altered expression and secretion of adipokines from
adipose tissue, increased production of pro-inflammatory
cytokines, and increased oxidative stress. While intensive
weight loss programs can be moderately successful [7],
two-thirds of the U.S. adult women are still overweight
or obese [8]. Thus, identification of chemoprevention
agents that correct the metabolic dysregulation associ-
ated with overweight and obesity, even in the absence
of weight loss, is a highly attractive strategy for lower-
ing breast cancer risk.
Metformin for reduction of obesity-associated breast
cancer risk
Metformin is a biguanide indicated as an adjunct to diet
and exercise to improve glycemic control in adults and
children with type 2 diabetes mellitus. It has been used
worldwide for over 40 years to treat type 2 diabetes, and
was approved in the United States by the Food and Drug
Administration as an antidiabetic in 1995 [9]. It is also
commonly used off-label for metabolic syndrome [10]
as well as polycystic ovary syndrome (PCOS) [11], a
condition also characterized by metabolic disturbance.
The major mechanism of metformin action in vivo
involves suppression of hepatic gluconeogenesis and
glucose output, which is associated with a decline in
circulating glucose concentration and a secondary de-
cline in insulin levels [12].
Metformin exerts favorable effects on multiple meta-
bolic disturbances that may lead to reduction of breast
cancer risk. In diabetics, metformin treatment resulted
in favorable changes in circulating levels of leptin and
adiponectin [13, 14]. In women with PCOS, metformin
has been shown to reduce circulating insulin levels
(reviewed by [11]), increase insulin-like growth factor
binding protein (IGF-BP) 1 [15, 16], decrease serum
testosterone and androstenedione levels [17, 18], and
increase serum sex steroid hormone binding globulin
[17, 18]. Reduction in serum insulin levels was also
observed in non-diabetic breast cancer patients with
metformin treatment [19]. Metformin has also been used
to treat weight gain induced by antipsychotic medications
[20]. It has also been investigated for weight loss in
overweight but otherwise healthy individuals with suc-
cess in some but not all studies, however, these trials
had small sample size and design limitations that likely
contributed to the inconsistent results across studies
(reviewed by [21]).
In addition to indirect effects, metformin may exert a
direct effect in mammary tissue through the activation
of the AMP-activated protein kinase (AMPK) signaling
pathway, leading to an antiproliferative effect and induc-
tion of apoptosis [22–25]. However, metformin is an
organic cation at physiological pH. Its cellular uptake
generally requires the presence of the cell surface trans-
porters such as organic cation transporters (OCT) 1, 2
or 3. It is not known whether normal human mammary
tissue expresses the transporters for metformin to exert
its direct effect. In a recent neoadjuvant trial, however,
expression of the OCT1 transporter was detected in
breast tissue [26].
Epidemiological and clinical evidence of metformin for
breast cancer prevention
Some, but not all case control and cohort studies inves-
tigating the relationship between diabetes and cancer
have found that treatment with metformin appears to
substantially reduce the risk for development of cancer
in individuals diagnosed with diabetes [27, 28], including
lower risk for breast cancer [29–32]. Some evidence also
suggests a role for metformin in prolonging breast
cancer survival [33, 34]. Given the retrospective nature
of these studies and the possibility that the compari-
son treatments (such as sulfonylureas or exogenous
insulin) may increase risk, randomized, placebo-
controlled intervention trials are needed to assess the
breast cancer preventive activity of metformin. It is
important to note that accumulating evidence suggests
that type 2 diabetes and obesity share biological mech-
anisms for their association with postmenopausal
breast cancer which include pathways targeted by met-
formin (reviewed by [35]). Therefore, metformin could
modify breast cancer risk in people with elevated BMI
independent of a diagnosis of diabetes.
Recent window-of-opportunity neoadjuvant trials re-
ported clinical activity of metformin in non-diabetic
women with operable invasive breast cancer. Two small
non-placebo controlled trials showed decreased tumor
cell proliferation following a short-term metformin
intervention prior to surgery [36, 37]. A considerably lar-
ger randomized, placebo-controlled trial (N = 200) did
not show an overall decrease in tumor cell proliferation
after 4 weeks of metformin intervention [38]. However,
subgroup analyses showed a decrease in tumor cell
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proliferation and serum insulin levels in women with
high waist/hip ratio or insulin resistance, suggesting the
importance of the metabolic characteristics of the study
population [38]. In a recent small trial with early stage
breast cancer patients, metformin administration signifi-
cantly decreased expression of the insulin receptor, pho-
phorylated protein kinase B (PKB), and phosphorylated
extracellular signal-regulated kinase 1/2 (ERK 1/2) in
tumor tissue [26], suggesting a therapeutic benefit.
An ongoing, large Phase III randomized trial (NCIC
CTG MA.32) in over 3,500 early stage breast cancer
patients aims to determine whether adding metformin
to standard adjuvant therapy will improve invasive dis-
ease free survival. Recently published interim data from
this trial shows a statistically significant decrease in
weight, insulin, glucose, leptin, and CRP at six months
in the metformin arm verses placebo [39]. The outcomes
of this trial will be important in assessing metformin’s
effectiveness on recurrence and survival in breast cancer
patients. However, the majority of the study population
has received standard adjuvant radiation, endocrine
treatment, trastuzumab or other biologics or bispho-
sphonates prior to or during study treatment, or ad-
juvant or neoadjuvant chemotherapy prior to study
treatment. In general, applicability of the data gener-
ated from this trial to a potential role for metformin as
a single agent for breast cancer risk reduction in at-
risk women with no prior breast cancer history is un-
clear and requires further research. Our study is one of
the first placebo controlled trials to evaluate the effect
of metformin on breast cancer risk factors in at risk
healthy women.
Overall study goals
The overall objective of our study is to evaluate the ef-
fect of metformin on biomarkers that have shown strong
clinical and scientific relevance to breast cancer risk and
have high potential to be modulated by metformin in a
cohort of overweight premenopausal women. The pri-
mary study aim is to determine the effect of metformin
on breast density. Studies suggest that women with
dense tissue in more than 60–75 % of the breast are at
4-6-fold greater risk of developing breast cancer than
those with no dense tissue [40–42]. We hypothesize that
metformin intervention will reduce breast density be-
cause metformin has been shown to decrease breast cell
proliferation and modulate the IGF axis [15, 16, 36, 37],
which have both been associated with variation in breast
density [43–46]. Breast density will be assessed by
magnetic resonance imaging (MRI)-acquired fat-water
features, a novel, three-dimensional measure of breast
density that will provide more sensitive and quantitative
detection of changes in breast density than mammo-
graphic measure. The study is enrolling premenopausal
women instead of postmenopausal women because pre-
menopausal women have a higher breast density at
baseline, which may allow for more notable detection
of breast density reduction by metformin. Further, this
study population is at increased risk for future post-
menopausal breast cancer.
This study is one of the first placebo-controlled, ran-
domized trials to determine metformin effects on mul-
tiple metabolic disturbances as well as anthropometric
measures in non-diabetic women. In addition, we will
explore the application of metabolomics analysis to both
plasma and nipple aspirate fluid as a systems biology
approach to assess the potential chemopreventive mech-
anisms of metformin and to understand metabolic fea-
tures affecting systemic and tissue markers of breast
cancer risk. Metabolomic profiling in fluid expressed
from the breast may provide information about the
breast microenvironment that may not be reflected in
plasma. Further, we will also have the opportunity to ex-
plore breast-tissue level effects of metformin in a subset
of women. Thus, we will have the unique opportunity to
explore the associations between metabolic features in
nipple aspirate fluid and plasma with markers of breast
cancer risk in both plasma and in breast tissue to further
our understanding of the underlying biochemical mecha-
nisms affecting these risk markers. Findings from this
study will add insight into whether metformin can be
used clinically as a pharmacological approach for breast





The primary objective is to determine the effect of met-
formin intervention on breast density assessed by MRI
acquired fat-water features.
Secondary objectives
The secondary objectives are to determine the effect of
metformin intervention on metabolic disturbances and
body weight/composition, and to apply metabolomics as
a systems biology approach to assess the chemopreven-
tive mechanisms of metformin.
Exploratory objectives
An exploratory objective is to determine the effect of
metformin intervention on tissue architecture as well
as cellular and molecular targets in breast tissue col-
lected in a subgroup of participants. We will also ex-
plore whether metformin-induced metabolic changes
correlate with changes in markers of breast cancer risk
or side effects.
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Study design
This is a Phase II double-blind, randomized, placebo-
controlled trial of metformin to determine its potential
effects on recognized and putative markers of breast
cancer risk in overweight or obese premenopausal
women with elements of metabolic syndrome. Figure 1
illustrates the overall study design.
Participant recruitment
This is a single institution trial conducted at the University
of Arizona Cancer Center (UACC), USA. Women will be
recruited through clinic offices, television and radio adver-




 21–54 years of age
 No change in menstrual patterns for the past
6 months preceding the time of registration
 Have a body mass index of 25 kg/m2 or greater
 Large waist circumference:
○ ≥88 cm (≥35 in.) or
○ ≥80 cm (≥31 in.) for Asian Americans,
individuals with PCOS, or individuals with
non-alcoholic fatty liver disease
 Have at least one other component of metabolic
syndrome [47]:
○ Elevated triglycerides (≥150 mg/dL (1.7 mmol/L))
or on drug treatment for elevated triglycerides,
○ Reduced high-density lipoprotein cholesterol
(<50 mg/dL (1.3 mmol/L)) or on drug treatment
for reduced high-density lipoprotein cholesterol,
○ Elevated blood pressure (≥130 mmHg systolic
blood pressure or ≥85 mmHg diastolic blood
pressure) or on antihypertensive drug treatment
in a patient with a history of hypertension, or
○ Elevated fasting glucose (≥100 mg/dL)
 Mammogram negative for breast cancer within the
12 months preceding the time of registration for
women ≥ 50 years of age
 Ability to understand and willingness to sign a
written informed consent document
Exclusion criteria
 Postmenopausal women
○ Amenorrhea for at least 12 months (preceding
the time of registration), or
○ History of hysterectomy and bilateral salpingo-
oophorectomy, or
○ At least 55 years of age with prior hysterectomy
with or without oophorectomy, or
○ Age 35 to 54 with a prior hysterectomy
without oophorectomy OR with a status of
ovaries unknown with documented follicle-
stimulating hormone level demonstrating
elevation in postmenopausal range
 Women who are pregnant, planning pregnancy
within the next year, or lactating/breastfeeding
 On treatment with any drug for diabetes
 Have uncontrolled intercurrent illness including,
but not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or any illness that
would limit compliance with study requirements
 Have received chemotherapy and/or radiation for
any malignancy (excluding non-melanoma skin
cancer and cancers confined to organs with
removal as only treatment) in the past 5 years
(preceding the time of registration)
 Have received other investigational agents within
the past 3 months (preceding the time of registration)
 Have a history of lactic acidosis or risk factors for
lactic acidosis
 Have renal disease or dysfunction (creatinine ≥
1.4 mg/dL)
Fig. 1 Overall study design. MRI: magnetic resonance imaging; NAF: nipple aspirate fluid
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 Have hepatic dysfunction (bilirubin > 1.5 × ULN unless
with Gilberts syndrome or AST/ALT > 3 × ULN)
 Have a history of alcoholism or high alcohol
consumption (average of > 3 standard drinks/day)
 Have a history of allergic reactions to metformin
or similar drugs
 Have a history of severe claustrophobia
 Have electrically, magnetically, or mechanically
activated implants including cardiac pacemaker,
cochlear implants, magnetic surgical clips or prostheses
 Have breast implants
Randomization
Randomization is performed using computer-generated
random permuted blocks. To retain the blind, met-
formin and placebo supplies are identified by the
randomization number. The study staff will dispense
the product to subjects based on the assigned rando-
mization number. None of the staff interacting with
subjects will know the link between randomization
number and actual product. The code that identifies
the product will be kept by the study statistician or
the designated data manager.
Unblinding is not expected to occur until all subjects
complete the intervention and data entry is complete.
If deemed medically necessary, study agents may be
unblinded by the Principle Investigator in consultation
with the Medical Director in the event of a serious
adverse event (SAE).
Agent administration
Subjects will be on agent intervention for 12 months
(52 ± 4 weeks). For the first four weeks, 1 metformin
(850 mg) or placebo tablet will be taken once daily with
food. For the remaining treatment period, metformin or
placebo tablets will be taken twice daily with food.
Concomitant medications
Participants may not use non-study metformin or other
biguanides while on study. Medications with potential
interaction with metformin (e.g. cationic drugs) will be
carefully reviewed and monitored closely while subjects
are on study. All medications (prescription and over-
the-counter), vitamin and mineral supplements, and/or
herbs taken by the participant will be documented on
the concomitant medication case report form and
include: start and stop date, dose and route of adminis-
tration, and indication.
Schedule of study procedures
A schedule of study procedures is presented in Table 1.
Consent to participate
Potential subjects will present to clinic for a detailed dis-
cussion of the protocol with the study coordinator.
Signed informed consent will be obtained prior to any
study-related activities or procedures being conducted.
Subjects are registered onto the protocol on the day of
consent. Participants will then undergo the following
procedures for screening.
 Review of medical history and medication usage
history
 Collection of demographic information
(age, race/ethnicity)
 Collection of anthropometric measurements
(weight, height, waist circumference, waist-hip ratio)
 Collection of breast cancer risk information
(family and personal history of breast cancer,
age at menarche, parity, and prior breast biopsy)
 Collection of information on menstrual patterns/cycles
 Measures of vital signs (temperature, blood pressure
and pulse).
 A fasting blood sample for complete blood count
with differential (CBC/w diff ), comprehensive
metabolic panel (CMP), lipids, and follicle-
stimulating hormone and/or estradiol for
women with uncertain menopausal status
 Urine pregnancy test
Baseline procedures
Participants who meet all selection criteria will undergo
the following baseline procedures. When feasible, these
procedures will be scheduled in the midluteal phase of
the menstrual cycle.
 Anthropometric measurements
 A fasting blood for research biomarkers
 Collection of urine for urine pregnancy test and
research tests
 Vital signs
 Update information on menstrual patterns/cycles
 Update medication usage
 Completion of the Arizona Food Frequency
Questionnaire (AFFQ) to measure usual dietary
intake and the Arizona Activity Frequency
Questionnaire (AAFQ) to assess usual physical activity
 Collection of nipple aspirate fluid (NAF)
 MRI assessment of breast density – MRI is
performed on a Seimens 3T MRI system using a
16 channel breast MRI coil system. Fat-water maps
will be obtained using a multi-point Gradient Echo
DIXON imaging method developed by Siemens
[48–50]. Women who cannot fit into the MRI
scanner due to large body size will continue the
study and undergo all other study procedures
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(52 ± 4 weeks)
Follow up
Consent, med records release form x
Medical history, performance status x
Anthropometric measurements x x x x
Vital signs (Temp, BP, Pulse) x x x x x x
Concomitant meds x x x x x x
Breast cancer risk questionnaire x
Menstrual pattern/cycle review x x x x x x
Menstrual cycle diary x x x x x x x x x x
Fasting blood (CBC/Diff, CMP, lipids, FSHa, estradiola) x x
Fasting blood for research endpoints x x x
Urine pregnancy test x x x x x x
Urine for research endpoints x x x
AFFQ, AAFQb x x
Nipple aspirate fluid (NAF) collection x x x
Breast MRIc x x x
Core biopsy, if consented x x
Final eligibility assessment x
Randomization x
Dispense study agent x x
Intake calendar x x x x x x x x
Adverse events diary x x x x x x x x x x
Adverse events review x x x x x x
Return study agent x x
Compliance assessment x x x x
Case report form completion x x x x x x x
Telephone/email contactd x x x x
aFSH (follicle-stimulating hormone) and/or estradiol at screening for women with uncertain menopausal status
bAFFQ: Arizona Food Frequency Questionnaire; AAFQ: Arizona Activity Frequency Questionnaire
cWomen who cannot fit into the MRI scanner due to the large body size will continue the study and undergo all other study procedures
dStudy personnel will contact subjects within a week after study agent has been initiated and within a week following scheduled dose increase to assess compliance and any potential problems. Additional periodic












 Optional core needle biopsy - for participants who
consent to this optional procedure, the medical
specialist will use a 14-gauge needle under ultrasound
guidance to obtain up to 8 tissue cores from areas
of high density in one of the breasts
Following completion of baseline evaluation, partici-
pants will be randomized to receive metformin or pla-
cebo for 12 months. Participants will be asked to keep
an adverse event (AE) diary and menstrual calendar
throughout the study. In addition, participants will be
provided with an intake calendar for recording medica-
tion usage. Study personnel will contact study partici-
pants within a week after study agent has been initiated
and within a week following the scheduled dose increase
to assess compliance and any potential problems.
6-month visit procedures
Participants will return at month 6 (26 ± 4 weeks) to
undergo the following procedures:
 Collection of urine for urine pregnancy test and
research tests
 Vital signs
 Update information on menstrual patterns/cycles
 Update medication usage
 Side effect evaluation
 Return unused pills
 Receive a new supply of study medication
 Anthropometric measurements
 Collection of a fasting blood and NAF sample for
research biomarkers
 MRI assessment of the breast
 Optional breast core biopsy
When feasible, the month 6 procedures will be sched-
uled in the mid-luteal phase of the menstrual cycle.
Completion of study intervention procedures
Participants will be instructed to take the study agent
until the day of the last study procedure. At the end of
the 12-month agent intervention (52 ± 4 weeks), partici-
pants will return to the clinic to undergo the following
procedures:
 Collection of urine for urine pregnancy test and
research tests
 Vital signs
 Update information on menstrual patterns/cycles
 Update medication usage
 Return unused pills
 Side effects evaluation
 Anthropometric measurements
 A fasting blood for CBC/CMP/lipids and research
biomarkers
 NAF collection
 MRI assessment of breast density
 Completion of AFFQ and AAFQ
When feasible, the month 12 procedures will be sched-
uled in the midluteal phase of the menstrual cycle.
After completing the study intervention, participants
will be followed for 2 weeks for any adverse reactions.
Additional visit procedures
Throughout the study, study personnel will contact
study participants as needed between clinic visits to as-
sess compliance and any potential problems. In addition
to clinic visits with study endpoint collections, partici-
pants will return to the clinic at month 3 (13 ± 2 weeks)
and month 9 (39 ± 2 weeks) after initiation of agent
intervention in order to conduct a urine pregnancy test,
obtain vital signs, update menstrual cycle information,
update medication usage, and to evaluate side effects to
ensure safety as well as participant compliance.
Safety
All AEs will be assessed according Common Terminology
Criteria for Adverse Events Version 4, followed according
to good medical practices, and documented.
Data and safety monitoring
The University of Arizona Cancer Center (UACC) Data
and Safety Monitoring Board (DSMB) will provide on-
going oversight for this trial. Routine monitoring will
be provided by the UACC Quality Assurance/Quality
Control (QA/QC) Program to ensure that the investi-
gation is conducted according to protocol design and
regulatory requirements. The Principal Investigator will
ensure the accuracy, completeness, legibility and time-
liness of the data reported in the Case Report Form
(CRF). Source documentation supporting the CRF data
will indicate the participant’s participation in the trial
and should document the dates and details of study
procedures, AEs, and participant status.
Details of power calculation and sample size
Our sample size ensures adequate power to test all primary
and secondary outcomes. We assume an initial sample size
of 75 women per group and allow the possibility of up to
20 % dropout for the 12-month follow-up measurement,
resulting in at least 60 evaluable women per group. To de-
termine the detectable effect size, we use a simplified com-
parison of change between 12 months versus baseline,
assuming a two-sided α of 0.05 and 80 % statistical power.
For the fat-water MRI-derived change in breast density, we
will be able to detect a decrease of 0.516 standard deviation
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(SD) units in the metformin treated women, equivalent to
a 10 % decrease in breast density as determined by stand-
ard mammography. For the secondary outcomes (such as
systemic hormones, cytokines, and weight), we will also be
able to detect a difference of 0.516 SD units. For metabolo-
mic analysis that compares thousands of metabolites, we
approximated the effect size by setting a more stringent
alpha level of 0.005. For plasma metabolomic analysis we
will be able to detect an effect size of 0.667 SD units, while
for NAF metabolomic analysis we will be able to detect an
effect size of 0.848 SD units (assuming at least 65 % of the
women will provide sufficient NAF).
Statistical analysis
The primary study endpoint is to compare the change in
breast density as measured by fat-water MRI (when
measured at baseline, 6 and 12 months) between metfor-
min and placebo groups. Additional endpoints such as
systemic hormone and cytokines, body weight, waist
circumference, and waist-hip ratio will be measured at
baseline, 6 and 12 months. Analysis for all study end-
points will be based on a linear mixed-effects model for
the observed values across time, to adjust for the cor-
relation among measurements within the same woman.
The main effects in the model will be time (0, 6, 12),
treatment group (metformin versus placebo), and the
interaction between time and treatment group. The
time parameter tests if there is a change among placebo
treated women, while the group-by-time interaction
tests if the change in metformin treated women differs
from that in the placebo group. We expect that a sim-
pler covariance structure, such as compound symmetry,
will be adequate for repeated measurements within the
same woman (since the measurements are equally spaced).
Alternatively, we will compare correlation structures for
the longitudinal measurements using Akaike’s information
criterion. All endpoints will be assessed for normality,
and transformations (such as a logarithmic transfor-
mation) will be used as necessary to reduce skewness
prior to statistical analysis.
For the metabolomic aim, pre- to post-intervention
changes in all detectable compounds will be determined
and compared between treatment groups using two-
sample t-tests. An estimate of the false discovery rate (q-
value) will be calculated [51] to adjust for the multiple
comparisons that normally occur in metabolomic-based
studies. A low q-value (q ≤ 0.10) is an indication of high
confidence in a result. While a higher q-value indicates
diminished confidence, it does not necessarily rule out
the significance of a result. Other lines of evidence may
be taken into consideration when determining whether a
result merits further scrutiny. Such evidence may include
a) significance in another dimension of the study, b) in-
clusion in a common pathway with a highly significant
compound, or c) residing in a similar functional bio-
chemical family with other significant compounds.
No interim statistical analyses are planned for this
Phase II trial. Accrual, data collection, and any AEs will
be monitored on a regular basis. The final dataset will
be available to all study investigators.
Discussion
The trial was activated in March of 2014. As of May, 2016,
we have consented 152 women. Fifty were ineligible, 5
dropped out prior to agent intervention, 97 initiated agent
intervention. It is expected that we will complete accrual
by the summer of 2017 and participant treatment by the
summer of 2018. Over 80 % of the accrued participants
have agreed to undergo the optional breast biopsy. Find-
ings from this study will be published in a peer-reviewed
scientific journal and will have wide public health impact
because of the growing overweight and obese populations
at risk for multiple diseases. With its demonstrated effect
in reducing the incidence of diabetes in high-risk adults
[52], metformin would have a high level of acceptance and
uptake in at risk women with high adiposity if it has also
been shown to exert favorable activities in breast cancer
risk reduction. Considering the challenges in maintaining
a healthy life style by the majority of the general public
and the pleiotropic activities of metformin for multiple
metabolic disorders, metformin could be developed as
an integrated pharmacological approach for at risk
women with high adiposity for prevention of multiple
chronic diseases including breast cancer.
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